Literature DB >> 29980847

The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.

Shinya Maekawa1, Nobuyuki Enomoto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29980847     DOI： 10.1007/s00535-018-1493-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  8 in total

Review 1.  Impact of new treatment options for hepatitis C virus infection in liver transplantation.

Authors:  Elda Righi; Angela Londero; Alessia Carnelutti; Umberto Baccarani; Matteo Bassetti
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Authors:  Stefan Zeuzem; Graham R Foster; Stanley Wang; Armen Asatryan; Edward Gane; Jordan J Feld; Tarik Asselah; Marc Bourlière; Peter J Ruane; Heiner Wedemeyer; Stanislas Pol; Robert Flisiak; Fred Poordad; Wan-Long Chuang; Catherine A Stedman; Steven Flamm; Paul Kwo; Gregory J Dore; Gladys Sepulveda-Arzola; Stuart K Roberts; Ruth Soto-Malave; Kelly Kaita; Massimo Puoti; John Vierling; Edward Tam; Hugo E Vargas; Rafi Bruck; Francisco Fuster; Seung-Woon Paik; Franco Felizarta; Jens Kort; Bo Fu; Ran Liu; Teresa I Ng; Tami Pilot-Matias; Chih-Wei Lin; Roger Trinh; Federico J Mensa
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

Review 3.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

4.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Authors:  Masashi Mizokami; Osamu Yokosuka; Tetsuo Takehara; Naoya Sakamoto; Masaaki Korenaga; Hitoshi Mochizuki; Kunio Nakane; Hirayuki Enomoto; Fusao Ikeda; Mikio Yanase; Hidenori Toyoda; Takuya Genda; Takeji Umemura; Hiroshi Yatsuhashi; Tatsuya Ide; Nobuo Toda; Kazushige Nirei; Yoshiyuki Ueno; Yoichi Nishigaki; Juan Betular; Bing Gao; Akinobu Ishizaki; Masa Omote; Hongmei Mo; Kim Garrison; Phillip S Pang; Steven J Knox; William T Symonds; John G McHutchison; Namiki Izumi; Masao Omata
Journal:  Lancet Infect Dis       Date:  2015-04-08       Impact factor: 25.071

Review 5.  Sofosbuvir and velpatasvir for the treatment of hepatitis C.

Authors:  Whitney E Jackson; Gregory T Everson
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-05-11       Impact factor: 3.869

6.  Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.

Authors:  Keiji Tsuji; Masayuki Kurosaki; Jun Itakura; Nami Mori; Shintaro Takaki; Chitomi Hasebe; Takehiro Akahane; Kouji Joko; Hitoshi Yagisawa; Jirou Takezawa; Ryou Nakata; Atsunori Kusakabe; Yuji Kojima; Hiroyuki Kimura; Takashi Tamada; Haruhiko Kobashi; Akeri Mitsuda; Masahiko Kondou; Chikara Ogawa; Yasushi Uchida; Tetsuro Sohda; Ryouichi Narita; Namiki Izumi
Journal:  J Gastroenterol       Date:  2018-04-06       Impact factor: 6.772

Review 7.  Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region.

Authors:  Mi Na Kim; Beom Kyung Kim; Kwang-Hyub Han
Journal:  J Gastroenterol       Date:  2013-03-06       Impact factor: 7.527

8.  Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Authors:  Hiromitsu Kumada; Tsunamasa Watanabe; Fumitaka Suzuki; Kenji Ikeda; Ken Sato; Hidenori Toyoda; Masanori Atsukawa; Akio Ido; Akinobu Takaki; Nobuyuki Enomoto; Koji Kato; Katia Alves; Margaret Burroughs; Rebecca Redman; David Pugatch; Tami J Pilot-Matias; Preethi Krishnan; Rajneet K Oberoi; Wangang Xie; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2017-10-20       Impact factor: 7.527
  8 in total
  1 in total

1.  Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing.

Authors:  Kozue Yamauchi; Mitsuaki Sato; Leona Osawa; Shuya Matsuda; Yasuyuki Komiyama; Natsuko Nakakuki; Hitomi Takada; Ryo Katoh; Masaru Muraoka; Yuichiro Suzuki; Akihisa Tatsumi; Mika Miura; Shinichi Takano; Fumitake Amemiya; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Taisuke Inoue; Shinya Maekawa; Nobuyuki Enomoto
Journal:  Hepatol Commun       Date:  2022-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.